Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310351 | 0.77 | TDP1 (0.49) | ALDH1A1TDP1GPR35PDE10AKMT2A | |
| SCHEMBL1179475 | 0.76 | TDP1 (0.45) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL4306587 | 0.76 | TDP1 (0.61) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL5777939 | 0.74 | ALDH1A1 (0.47) | ALDH1A1TDP1GPR35PDE10AKMT2A | |
| SCHEMBL33832 | 0.74 | TDP1 (0.46) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL7136437 | 0.74 | TDP1 (0.46) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL41322 | 0.72 | GPR35 (0.54) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL2075134 | 0.72 | TDP1 (0.45) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL1036583 | 0.72 | TDP1 (0.45) | ALDH1A1TDP1GPR35KMT2ATSHR | |
| SCHEMBL7907932 | 0.72 | TDP1 (0.45) | ALDH1A1TDP1GPR35KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117983302-A | Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof | 华东理工大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-107315318-B | Photosensitive composition | 东京应化工业株式会社 | 2022-07-01 | — | — | CN | disclosed |
| CN-107311889-B | Compound and method for producing same | 东京应化工业株式会社 | 2022-01-14 | — | — | CN | disclosed |
| EP-2243805-B1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-101925658-B | Anthrapyridone compound or salt thereof, magenta ink composition containing anthrapyridone compound, and colored body | NIPPON KAYAKU KK | 2013-10-02 | — | — | CN | disclosed |
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| EP-2433496-A1 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | Burnham Institute for Medical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8119693-B2 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-21 | — | — | US | disclosed |
| US-7985287-B2 | Anthrapyridone compound or a salt thereof, magenta ink composition containing the anthrapyridone compound and colored product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| CN-1157288-A | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| CN-1118781-A | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 1996-03-20 | — | — | CN | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| US-3959277-A | Diimidazopyrazines and tetracarboxamidopyrazines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | ALDH1A1 1571/4885TDP1 1030/4885GPR35 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.